AdAlta Limited announce improved cell line development results for its lead fibrosis candidate, AD-214. Results are now above previously reported expression levels, at 3 grams per litre (3g/L), up from the 1g/L reported in October 2018. Importantly, the improved results mean the Company remains on track with the development of the manufacturing process for AD-214. It is on target to deliver Good Laboratory Practice (GLP) material for its four-week non-human primate toxicology study, which is expected to commence in July 2019 and be completed in second half of 2019. AdAlta is also on track to deliver Good Manufacturing Practice (GMP) material for its Phase 1 human study which is expected to commence in January 2020. The appointments of Selexis and KBI follow the announcement mid-last year that AdAlta would take forward an improved version of its lead therapeutic program for the treatment of Idiopathic Pulmonary Disease (IPF). This new version AD-214, is expected to deliver significantly improved half-life (duration of time the drug remains in the body), enhanced activity, and be applicable across a broader range of fibrotic disease areas, making it more attractive to patients and pharmaceutical partners.